Clinical Correlates of Immunotherapy

• 6453 · PDF Serum pharmacodynamic biomarkers of IPI/NIVO/RELA plus sarilumab in Stage III-IV melanoma: Stage 1 results of a Simon Phase II trial (NCT05428007) Teruyuki Mizutani, Amrutesh Puranik, Inderjit Mehmi, Judith Goldberg, Maya Dimitrova, Perla Arriola, Stanzin Idga, Xiaochun Li, Benjamin Levinson, Justine Cohen, Elizabeth I. Buchbinder, Donald Lawrence, Alissa Kalyan, Morgan Simons, F. Stephen Hodi, Ryan J. Sullivan, Omid Hamid, Michelle Krogsgaard, Janice M. Mehnert
• 6454 · PDF Enhanced monocyte activation and T cell cytotoxicity underlie the benefit of neoadjuvant durvalumab plus gemcitabine-cisplatin (D+GP) in localized biliary tract cancer (BTC): Phase 2 DEBATE study Changhoon Yoo, Hyung-Don Kim, Chang Yeon Kim, Joon Oh Park, Hyehyun Jeong, Kyu-Pyo Kim, Jung Yong Hong, Sang Hyun Shin, Tae Jun Song, Dongwook Oh, Woohyung Lee, Jae Hoon Lee, Dae Wook Hwang, Jeong Seok Lee
• 6455 · PDF Cytotoxic T-cell signatures underlie therapeutic response to 177Lu-DOTATATE plus pembrolizumab in well-differentiated gastroenteric neuroendocrine tumors Naoki Mizutani, Shloka Shukla, Nicholas Fidelman, Bridget P. Keenan, David Y. Oh, Kira Chan, Li Zhang, Emily K. Bergsland, Thomas Hope, Lawrence Fong
• 6456 · PDF Pan-tumor investigation of peripheral biomarkers of excellent response to anti-PD(L)1-based therapy Howard L. Li, Soren Charmsaz, Chester Kao, Carlotta Pazzi, Madelena Brancati, James Leatherman, Nicole E. Gross, Royce P. Lee, Xiyu Zhao, Christopher Thoburn, Jeannie Hoffman-Censits, Evan J. Lipson, Yasser Ged, Marina Baretti, G Scott Chandler, Rajat Mohindra, Laura Tang, Sanjay Bansal, Aditi Guha, Elizabeth Jaffee, Daniel J. Zabransky, Won Jin Ho, Mark Yarchoan, Mari Nakazawa
• 6457 · PDF Phase I study of STA551 (STA) a tumor-selective CD137 agonist, as monotherapy and in combination with atezolizumab (atezo) using CD8 PET imaging to assess pharmacodynamic effects Udai Banerji, Diogo Silva, Joshua Ting, Zoulikha Zair, Prakash Manoharan, Toshihiko Doi, Shigehiro Koganemaru, Noboru Yamamoto, Takafumi Koyama, Seiichi Ikeda, Yuki Kanai, Michiyasu Inatani, Hitomi Takeshita, Akiko Hashimoto, Yoshitaka Ogita, Yuma Takano, Kei Higashikawa, Fiona Thistlethwaite
• 6458 · PDF Harnessing tumor-informed B cell receptors for discovery and antibody-based immunotherapy in sarcoma Varshini Arunkumar, Manoj Chelvanambi, Joshua B. Plummer, Monika Zelazowska, Fabiana J. Veguilla, Elise Nassif Haddad, Noha M. Osman, Wei-Lien Wang, Davis Ingram, Khalida M. Wani, Angela Bhalla, Sharon M. Landers, Keila E. Torres, Jennifer A. Wargo, Bin Liu, Alexander Lazar, Neeta Somaiah, Christina L. Roland, Kevin McBride, Emily Z. Keung
• 6459 · PDF Development of FL115, a novel IL-15 superagonist, as subcutaneous injection for cancer immunotherapy Qinghua Wu, Quanxiao Li, Dong Wei
• 6460 · PDF Immunologic and transcriptional features associated with long-term response and resistance to immune checkpoint inhibitors in non-small cell lung cancer checkpoint inhibitors in non-small cell lung cancer Yoshihiro Masui, Tatsuya Yoshida, Jun Miyakoshi, Ryoko Higashiyama, Akiko Tateishi, Yuki Shinno, Tomonori Mizutani, Yusuke Okuma, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Yasushi Goto
• 6461 · PDF Comprehensive cytokine, chemokine and immune marker evaluation in plasma samples of primary, non-metastatic high grade serous ovarian cancer patients to estimate outcome and platinum resistance Sabine Kasimir-Bauer, Buesra Eser, Yipeng Wang, Gordon Vansant, Stefanos I. Moukas, Rainer Kimmig, Fabinshy Thangarajah
• 6462 · PDF Baseline peripheral immune signatures associate with toxicity to immunotherapy in melanoma Iluja Gautam, Patricia Rayman, Nickolas Stabellini, Jennifer Powers, Adam Moen, Brian Race, Paul Pavicic, Mona Patel, Alberto J. Montero, C. Marcela Diaz-Montero
• 6463 6463 Longitudinal single-cell atlas of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma identifies humoral and cellular anti-CAR immunity Yiyun Chen, Kun-Wei Song, Moksha H. Desai, Ying-Wen Huang, Nadya Iswari, Zachary J. Ehlinger, Hossein Daghagh, Maximilian R. A. Koch, Kevin Reynolds, Kelvin C. Mo, Kristin C. Y. Tsui, Skyler Rietberg, Mark P. Hamilton, Snehit Prabhu, Sonia Partap, Jasia Mahdi, Emily Egeler, Steven A. Feldman, Sabine Heitzeneder, Sean A. Yamada-Hunter, Elena Sotillo, Bita Sahaf, Zinaida Good, Michelle Monje, Sneha Ramakrishna, Crystal L. Mackall
• 6464 · PDF Surgery-induced expansion of myeloid-derived suppressor cells and loss of cytotoxic lymphocyte function predict poor survival in pancreatic cancer Olivia Johnsson, Malin S. Nilsson, Roberta Kiffin, Johan Bourghardt Fagman, Caroline Vilhav, Svein Olav Bratlie, Peter L J Naredi, Kristoffer Hellstrand, Anna Martner
• 6465 · PDF Validating tumor-infiltrating lymphocyte classification in primary cutaneous melanoma using cytokine immune scores: Addressing biomarker disparities in underserved populations Meshack Bida, Rodney Hull, Thabiso Miya, Tebogo Marutha, Zodwa Dlamini
• 6466 · PDF Preliminary results of a phase 2 study of leronlimab in combination with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer Pashtoon M. Kasi, Ari Baron, Arvind Chaudhry, Laura Tenner, Daniel L. Adams, Alexis B. Duffy, Hallgeir Rui, Patrick Vittner, Joseph Meidling, Jacob P. Lalezari
• 6467 · PDF Myeloma cells with therapy-induced senescence-like phenotype are associated with resistance to CAR-T therapy Sofia Arbelaez, Andre De Menezes Silva Corraes, Gabriel Alvares Borges, Chen Wu, Christoph Schaefers, Malvika Gupta, Zuoyi Shao, Kevin Regan, Rayaan Kamal, Angelo Jose Guilatco, Neal I. Sannuli, Ying Li, Taxiarchis Kourelis, Wilson Gonsalves, Moritz Binder, Melinda Tan, Nadine Abdallah, Megan Weivoda, Yi Lin
• 6468 · PDF Biopsy site-specific variation in immune signatures identified by RNA profiling in breast cancer Smruthy Sivakumar, Ericka Ebot, Douglas I. Lin, Meagan Montesion, Jeffrey S. Ross, Lee A. Albacker, Garrett M. Frampton, Michelle Marie Williams, Ethan S. Sokol
• 6469 · PDF Longitudinal loss of microbiome stability is associated with poor response to immune checkpoint inhibitors in lung cancer and melanoma Yujie Zhao, Jarushka Naidoo, Michael Conroy, Jacqueline T. Ferri, Joell J. Gills, Krista Y. Chen, James R. White, Sara Glass, Willaim O. Assan, Kimberly Peloza, Megan D. Schollenberger, William H. Sharfman, Kristen Marrone, Patrick M. Forde, Julie R. Brahmer, Valsamo (Elsa) Anagnostou, Drew M. Pardoll, Joseph Murray, Evan J. Lipson, Cynthia L. Sears, Fyza Y. Shaikh
• 6470 · PDF Spatial remodeling of the tumor microenvironment by IL-18-armored CD19 CAR T cells is associated with durable remission in relapsed or refractory lymphoma Nakial C. W. Cross, Yael A. Day, Sonia Ndeupen, Vanessa E. Gonzalez, Zhen Miao, Sam I. Kim, Rachel M. Leskowitz, Amy Marshall, Julie K. Jadlowsky, Gabriela Plesa, Donald L. Siegel, Elizabeth O. Hexner, Jakub Svoboda, Stephen J. Schuster, Nancy R. Zhang, Joseph A. Fraietta, Andrew J. Rech, Carl H. June
• 6471 · PDF Immune correlates post MMF omission lead to accelerated immune reconstitution without increased graft versus host disease risk signatures for allogenic stem cell transplant (OmitMMF trial) Vanshika Chauhan, Joseph Lownik, Larry Milshteyn, Haein Kim, Ronald Paquette, Akil Merchant
• 6472 6472 Tumor-cell NY-ESO-1 expression predicts poor response to PD-1/PD-L1 blockade in NSCLC Adele Lerue, Jean-Philippe Guegan, Christophe REY, Sophie Cousin, Benjamin Besse, Fabrice Barlesi, Christophe Massard, David Planchard, Alban Bessede, Antoine Italiano
• 6473 · PDF Clonal consolidation and transcriptional re-programming define non-small cell lung cancers resistant to immune checkpoint inhibitors Natalie Vokes, Arvind Ravi, Mark M. Awad, Patrick M. Forde, Marta Luksza, Benjamin Dylan Greenbaum, Adam Jacob Schoenfeld, John V. Heymach, Alice T. Shaw, Pasi A. Jänne, Jedd D. Wolchok, Matt Hellman, Gad Getz, JUSTIN GAINOR
• 6474 · PDF Robust and precise rare event analysis for immunotherapy clinical trials Chengsen Xue, Thomas W. Mc Closkey, Andew Roche
• 6475 · PDF Myeloma cells with therapy-induced senescence-like phenotype have increased resistance to killing by T cell directed therapies Christoph Schaefers, Angelo Jose Guilatco, Sofia Arbelaez, Gabriel Alvares Borges, Chen Wu, Andre de Menezes Silva Corraes, Malvika Gupta, Zuoyi Shao, Kevin Regan, Rayaan Kamal, Neal I. Sannuli, Ying Li, Taxiarchis Kourelis, Wilson Gonsalves, Melinda Tan, Nadine Abdallah, Yi Lin, Megan Weivoda
• 6476 · PDF Microbiome modulation via CBM588 dampens T cell exhaustion in patients with metastatic renal cell carcinoma on dual immune checkpoint blockade Colt A. Egelston, Miguel Zugman, Hedyeh Ebrahimi, Regina Barragan Carrillo, Nazli Dizman, Salvador Jaime-Casas, Xiaochen Li, Daniela V. Castro, Benjamin Mercier, Marice Alcantara, Motomichi Takahashi, Atsushi Hayashi, Tom Parks, Sumanta Kumar Pal, Peter P. Lee, Alexander Chehrazi-Raffle
• 6477 · PDF Peptide-based tumor-associated antigen vaccine in glioblastoma: Correlative results of the ETAPA Phase I clinical trial Elizabeth Owens, Kelly M. Hotchkiss, Pamela Norberg, Evan Buckley, Katayoun Ayasoufi, Stevie Threatt, Justin T. Low, Madison L. Shoaf, Melody Goldston, Kristen Batich, Margaret O. Johnson, James E. Herndon, Smita K. Nair, Kent Weinhold, Henry S. Friedman, David M. Ashley, Annick Desjardins, John H. Sampson, Mustafa Khasraw
• 6478 · PDF Temporal dynamics of T cell reprogramming associate with clinical response to ICI-based combination therapy in metastatic renal cell carcinoma KyuTae Hwang, Seowoo Kim, Mi Zhou, William Y. Kim, Minyong Kang
• 6479 6479 Immunotherapy and microbiota interventions as potential treatment options for anaplastic thyroid cancer Jocelynn G. Colunga Minutti, Naimah Turner, Synat Keam, Roza Nurieva

在会议检索中浏览本分会场